Sermorelin vs Tesamorelin: Uses, Evidence & Formulations

At a Glance: Side-by-Side Comparison

Mechanism: Correct the Structure Before Inferring Potency

Sermorelin is GHRH(1-29)-amide: the active, 29-amino-acid fragment at the beginning of human growth-hormone-releasing factor. It should not be confused with every modified GHRH peptide sold under similar names. National Library of Medicine sermorelin identity

Tesamorelin was developed from the 44-amino-acid human growth-hormone-releasing factor sequence with a trans-3-hexenoyl group attached at its beginning. This is a chemical modification, not six extra amino acids added to GHRH(1-29). The original nonclinical experiments found greater resistance to degradation; they did not establish a human head-to-head benefit over sermorelin. Original tesamorelin nonclinical study

Natural GHRH originates in the hypothalamus and stimulates pituitary GH release. EGRIFTA WR prescribing information

A study of ten healthy men measured a 4.3-minute disappearance half-time for GHRH(1-29)-amide after an intravenous infusion. Its D-Ala2-modified comparator lasted longer, but that comparator was not tesamorelin. This is not a universal subcutaneous sermorelin half-life. 1994 human GHRH pharmacokinetics study

After single subcutaneous doses in healthy participants, tesamorelin half-lives were 11 minutes for WR and 8 minutes for SV—not a matched potency comparison. EGRIFTA WR prescribing information EGRIFTA SV prescribing information

Efficacy: Compare Measured Outcomes, Not a Potency Score

A randomized trial in 412 adults with HIV and abdominal fat accumulation found that visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo over 26 weeks. It used daily subcutaneous 2 mg tesamorelin, an older formulation exposure rather than the current WR or SV dose. The study supports benefit in that population, not a head-to-head victory over sermorelin. 2007 randomized tesamorelin trial

In the extension of that trial, continued tesamorelin maintained an 18% reduction in visceral fat at 52 weeks; fat reaccumulated after treatment stopped. This is follow-up from the same trial, not an independent replication or evidence that the effect persists without treatment. 2008 extension of the tesamorelin trial

In a small before-and-after study, eleven men aged 64-76 with low baseline IGF-I received 2 mg GHRH(1-29) subcutaneously each night for six weeks. GH release increased, two of six strength measurements and an endurance test improved, but IGF-I and measured muscle and fat mass did not change. These findings do not establish an anti-aging regimen. 1997 nightly GHRH study

Ten older men received 0.5 mg and 1 mg GHRH(1-29) subcutaneously twice daily, each for 14 days with an untreated interval. GH and IGF-I increased at the higher exposure. These hormone findings do not establish a body-composition benefit or a universal treatment schedule. 1992 twice-daily GHRH study

US Status: Product Approval and Compounding Are Different Questions

WR and SV target excess abdominal fat in adults with HIV and lipodystrophy, not general weight loss. SV has no separate non-HIV weight-loss indication. EGRIFTA WR prescribing information EGRIFTA SV prescribing information

Geref's treatment product was approved in 1997 for children with idiopathic GH deficiency and growth failure; a separate diagnostic product was approved in 1990. Following 2008 discontinuation requests, approval withdrawal took effect on June 18, 2009. FDA determined in 2013 that the products had not been withdrawn for safety or effectiveness reasons. That history is not approval of every current compounded preparation. Official Geref withdrawal determination

Compounding is a real regulated pathway, distinct from product approval. Federal sections 503A and 503B impose different conditions, including ingredient and compounder requirements. A prescription alone does not establish that every condition is met, and this general framework is not a product-specific legal determination for a particular sermorelin preparation. The dispensing pharmacy should identify the product and applicable pathway. FDA compounding framework

The labeled WR dose is 1.28 mg (0.16 mL) subcutaneously daily. Its 11.6 mg vial uses 1.3 mL of supplied bacteriostatic water; after mixing, keep at 20-25°C and discard after seven days. Do not refrigerate or freeze it. WR and SV are not substitutable. EGRIFTA WR prescribing information

SV uses 1.4 mg (0.35 mL) subcutaneously daily. Mix its 2 mg vial with 0.5 mL of supplied sterile water; use immediately and discard leftovers. Do not refrigerate or freeze the mixed solution. Follow the exact product instructions. EGRIFTA SV prescribing information

Safety: Measured Risks, Not a Gentler-versus-Stronger Ranking

Tesamorelin labeling identifies elevated IGF-I, fluid retention, glucose intolerance or diabetes, and hypersensitivity. Allergic reactions are possible; a claim that pharmaceutical quality eliminates them is incorrect. These are monitoring and treatment-selection issues, not proof that every patient will experience them. EGRIFTA SV prescribing information

In the 26-week HIV trial, overall adverse-event frequency did not differ significantly, but more tesamorelin participants stopped because of an adverse event. A favorable overall tolerability description can coexist with clinically important risks. 2007 randomized tesamorelin trial

The small six-week GHRH(1-29) study reported no significant adverse effects. That observation does not establish a lower long-term risk than tesamorelin or justify applying invented shared side-effect percentages to both products. 1997 nightly GHRH study

Treatment Selection Starts with the Diagnosis

Tesamorelin is contraindicated with hypothalamic-pituitary-axis disruption, active malignancy, relevant hypersensitivity or pregnancy. Reduced pituitary reserve is therefore not a reason to recommend a stronger GHRH signal without evaluating its cause. EGRIFTA WR prescribing information

Historical pediatric Geref use should not become a recommendation for every adult with low-normal GH, and neither a hormone increase nor a user report establishes a longevity benefit. Diagnosis, the actual preparation and the outcome sought must come before selecting a peptide.

Users may describe improved recovery, energy or sleep. Those experiences can be discussed as anecdotes, while recognizing concurrent treatment, training and expectations. The studies reviewed here do not establish an anti-aging winner.

Cost: Confirm the Product, Coverage and Eligibility

EGRIFTA WR's manufacturer directs patients to THERA patient support. Commercially insured patients may qualify for copay assistance, and a separate assistance program offers medication at no cost to qualifying patients. These are eligibility-dependent programs, not promises of coverage or a fixed copay. Official THERA patient support

A useful comparison requires a current quote for the actual product, prescribed supply, consultations, laboratory monitoring and supplies. An old monthly range cannot establish today's out-of-pocket cost, and a lower quoted price does not establish that two preparations have equivalent evidence or quality.

Clinical Research Beyond the Main Indication

A 12-month randomized trial in people with HIV and fatty-liver disease tested tesamorelin 2 mg once daily against placebo. Hepatic fat fraction fell by 4.1 percentage points more with tesamorelin, corresponding to a 37% relative reduction from baseline. This research exposure is not the current WR or SV dose, and the finding is not approval for general weight loss or every form of fatty-liver disease. 2019 HIV-associated fatty-liver trial

For athletes governed by WADA rules, both sermorelin and tesamorelin appear in the growth-hormone-releasing-factor category prohibited at all times. Medical prescribing and sports eligibility are different questions; athletes should check applicable therapeutic-use requirements with their anti-doping organization. Claims that either is harder to detect are not established here. WADA Prohibited List